The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

Juris J Meier; Arnica Gethmann; Michael A Nauck; Oliver Götze; Frank Schmitz; Carolyn F Deacon; Baptist Gallwitz; Wolfgang E Schmidt; Jens J Holst

doi:10.1152/ajpendo.00576.2005

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

Juris J Meier, Arnica Gethmann, Michael A Nauck, Oliver Götze, Frank Schmitz, Carolyn F Deacon, Baptist Gallwitz, Wolfgang E Schmidt, Jens J Holst

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

95 Citationer (Scopus)

Abstract

Udgivelsesdato: 2006-Jun

Originalsprog	Engelsk
Tidsskrift	American Journal of Physiology: Endocrinology and Metabolism
Vol/bind	290
Udgave nummer	6
Sider (fra-til)	E1118-23
ISSN	0193-1849
DOI	https://doi.org/10.1152/ajpendo.00576.2005
Status	Udgivet - 2006

Bibliografisk note

Keywords: Adult; Blood Glucose; C-Peptide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Insulin; Lipid Metabolism; Male; Peptides; Time Factors

Adgang til dokumentet

10.1152/ajpendo.00576.2005

Citationsformater

Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006). The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. American Journal of Physiology: Endocrinology and Metabolism, 290(6), E1118-23. https://doi.org/10.1152/ajpendo.00576.2005

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. / Meier, Juris J; Gethmann, Arnica; Nauck, Michael A et al.
I: American Journal of Physiology: Endocrinology and Metabolism, Bind 290, Nr. 6, 2006, s. E1118-23.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Meier, JJ, Gethmann, A, Nauck, MA, Götze, O, Schmitz, F, Deacon, CF, Gallwitz, B, Schmidt, WE & Holst, JJ 2006, 'The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.', American Journal of Physiology: Endocrinology and Metabolism, bind 290, nr. 6, s. E1118-23. https://doi.org/10.1152/ajpendo.00576.2005

@article{9f7cdc40ab4b11ddb5e9000ea68e967b,

title = "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.",

abstract = "Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7-36) amide is degraded to the metabolite GLP-1-(9-36) amide. The effects of GLP-1-(9-36) amide in humans are less well characterized. Fourteen healthy volunteers were studied with intravenous infusion of GLP-1-(7-36) amide, GLP-1-(9-36) amide, or placebo over 390 min. After 30 min, a solid test meal was served, and gastric emptying was assessed. Blood was drawn for GLP-1 (total and intact), glucose, insulin, C-peptide, and glucagon measurements. Administration of GLP-1-(7-36) amide and GLP-1-(9-36) amide significantly raised total GLP-1 plasma levels. Plasma concentrations of intact GLP-1 increased to 21 +/- 5 pmol/l during the infusion of GLP-1-(7-36) amide but remained unchanged during GLP-1-(9-36) amide infusion [5 +/- 3 pmol/l; P < 0.001 vs. GLP-1-(7-36) amide administration]. GLP-1-(7-36) amide reduced fasting and postprandial glucose concentrations (P < 0.001) and delayed gastric emptying (P < 0.001). The GLP-1 metabolite had no influence on insulin or C-peptide concentrations. Glucagon levels were lowered by GLP-1-(7-36) amide but not by GLP-1-(9-36) amide. However, the postprandial rise in glycemia was reduced significantly (by approximately 6 mg/dl) by GLP-1-(9-36) amide (P < 0.05). In contrast, gastric emptying was completely unaffected by the GLP-1 metabolite. The GLP-1 metabolite lowers postprandial glycemia independently of changes in insulin and glucagon secretion or in the rate of gastric emptying. Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide.",

author = "Meier, {Juris J} and Arnica Gethmann and Nauck, {Michael A} and Oliver G{\"o}tze and Frank Schmitz and Deacon, {Carolyn F} and Baptist Gallwitz and Schmidt, {Wolfgang E} and Holst, {Jens J}",

note = "Keywords: Adult; Blood Glucose; C-Peptide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Insulin; Lipid Metabolism; Male; Peptides; Time Factors",

year = "2006",

doi = "10.1152/ajpendo.00576.2005",

language = "English",

volume = "290",

pages = "E1118--23",

journal = "American Journal of Physiology: Endocrinology and Metabolism",

issn = "0193-1849",

publisher = "American Physiological Society",

number = "6",

}

TY - JOUR

T1 - The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

AU - Meier, Juris J

AU - Gethmann, Arnica

AU - Nauck, Michael A

AU - Götze, Oliver

AU - Schmitz, Frank

AU - Deacon, Carolyn F

AU - Gallwitz, Baptist

AU - Schmidt, Wolfgang E

AU - Holst, Jens J

N1 - Keywords: Adult; Blood Glucose; C-Peptide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Insulin; Lipid Metabolism; Male; Peptides; Time Factors

PY - 2006

Y1 - 2006

N2 - Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7-36) amide is degraded to the metabolite GLP-1-(9-36) amide. The effects of GLP-1-(9-36) amide in humans are less well characterized. Fourteen healthy volunteers were studied with intravenous infusion of GLP-1-(7-36) amide, GLP-1-(9-36) amide, or placebo over 390 min. After 30 min, a solid test meal was served, and gastric emptying was assessed. Blood was drawn for GLP-1 (total and intact), glucose, insulin, C-peptide, and glucagon measurements. Administration of GLP-1-(7-36) amide and GLP-1-(9-36) amide significantly raised total GLP-1 plasma levels. Plasma concentrations of intact GLP-1 increased to 21 +/- 5 pmol/l during the infusion of GLP-1-(7-36) amide but remained unchanged during GLP-1-(9-36) amide infusion [5 +/- 3 pmol/l; P < 0.001 vs. GLP-1-(7-36) amide administration]. GLP-1-(7-36) amide reduced fasting and postprandial glucose concentrations (P < 0.001) and delayed gastric emptying (P < 0.001). The GLP-1 metabolite had no influence on insulin or C-peptide concentrations. Glucagon levels were lowered by GLP-1-(7-36) amide but not by GLP-1-(9-36) amide. However, the postprandial rise in glycemia was reduced significantly (by approximately 6 mg/dl) by GLP-1-(9-36) amide (P < 0.05). In contrast, gastric emptying was completely unaffected by the GLP-1 metabolite. The GLP-1 metabolite lowers postprandial glycemia independently of changes in insulin and glucagon secretion or in the rate of gastric emptying. Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide.

AB - Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7-36) amide is degraded to the metabolite GLP-1-(9-36) amide. The effects of GLP-1-(9-36) amide in humans are less well characterized. Fourteen healthy volunteers were studied with intravenous infusion of GLP-1-(7-36) amide, GLP-1-(9-36) amide, or placebo over 390 min. After 30 min, a solid test meal was served, and gastric emptying was assessed. Blood was drawn for GLP-1 (total and intact), glucose, insulin, C-peptide, and glucagon measurements. Administration of GLP-1-(7-36) amide and GLP-1-(9-36) amide significantly raised total GLP-1 plasma levels. Plasma concentrations of intact GLP-1 increased to 21 +/- 5 pmol/l during the infusion of GLP-1-(7-36) amide but remained unchanged during GLP-1-(9-36) amide infusion [5 +/- 3 pmol/l; P < 0.001 vs. GLP-1-(7-36) amide administration]. GLP-1-(7-36) amide reduced fasting and postprandial glucose concentrations (P < 0.001) and delayed gastric emptying (P < 0.001). The GLP-1 metabolite had no influence on insulin or C-peptide concentrations. Glucagon levels were lowered by GLP-1-(7-36) amide but not by GLP-1-(9-36) amide. However, the postprandial rise in glycemia was reduced significantly (by approximately 6 mg/dl) by GLP-1-(9-36) amide (P < 0.05). In contrast, gastric emptying was completely unaffected by the GLP-1 metabolite. The GLP-1 metabolite lowers postprandial glycemia independently of changes in insulin and glucagon secretion or in the rate of gastric emptying. Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide.

U2 - 10.1152/ajpendo.00576.2005

DO - 10.1152/ajpendo.00576.2005

M3 - Journal article

C2 - 16403774

SN - 0193-1849

VL - 290

SP - E1118-23

JO - American Journal of Physiology: Endocrinology and Metabolism

JF - American Journal of Physiology: Endocrinology and Metabolism

IS - 6

ER -